-
Too many confounding factors to conclude that there is an association between melatonin use and increased congestive heart failure risk
Medical Mythbusting Commentary for September 8, 2026 Source:Melatonin Use Linked to Massively Increased Risk of Heart Failure Reference:Long-term melatonin use linked to 90% higher heart failure risk
-
Targeted gene-altering therapy reduced LDL-cholesterol levels by 50 per cent in patients with severely elevated cholesterol levels.
Medical Mythbusting Commentary for September 2, 2026 Source:With the snip of a gene, scientists hope to erase high cholesterol for life Reference:Phase 1 Trial of CRISPR-Cas9 Gene Editing Targeting ANGPTL3
-
Newer understanding of new blood vessel growth after heart attack may lead to treatments to promote better bypass circulation.
Medical Mythbusting Commentary for August 24, 2026 Source:Your Heart Can Actually Build Its Own Bypass After a Heart Attack Reference:Tracing the origins of de novo coronary collateral formation in cardiac repair
-
Phase 1 targeted gene editing study demonstrates safety and reduction in LDL cholesterol levels through specific protein pathway
Medical Mythbusting Commentary for August 17, 2026 Source:‘An extremely exciting milestone!’: landmark treatment slashes cholesterol by 62% with a single dose Reference:In Vivo Base Editing of PCSK9 with VERVE-102 for Hypercholesterolemia
-
Beta-blockers, taken by millions after a heart attack, found to be ineffective for people with uncomplicated heart attacks (normal heart function thereafter) and presents increased risk of harm to women. Changes to management likely in the works for this population.
Medical Mythbusting Commentary for May 27, 2026 Source:Common heart drug taken by millions found useless — and possibly dangerous Reference:Beta-Blockers after Myocardial Infarction without Reduced Ejection Fraction Beta-blockers after myocardial infarction: effects according to sex in the REBOOT trial
-
Remnant cholesterol levels found to be an independent risk factor for heart disease. We discuss what this is and what the approach to management entails.
Medical Mythbusting Commentary for May 26, 2026 Source:Experts have found a new type of cholesterol. And it could be the most dangerous Reference: Source: openevidence.comRemnant cholesterol — defined as total cholesterol minus LDL-C minus HDL-C — is an emerging and increasingly recognized causal risk factor for ASCVD. Management centers on lifestyle modification as first-line therapy,…
-
Origami DNA nanocapsules being studied for its ability to deliver medications in narrowed or clogged arteries, releasing clot-busting or plaque-clearing drugs exactly where needed. In vivo studies to hopefully follow.
Medical Mythbusting Commentary for May 12, 2026 Source:Israel is building tiny robots that protect your heart Reference:Engineering a Mechanoresponsive DNA Origami Capsule for Drug Delivery to Narrowed Arteries
-
New way to lower high cholesterol by stopping its production demonstrated in mice. It is also designed for a subset of people with a genetically inherited condition that causes significant elevated levels.
Medical Mythbusting Commentary for April 17, 2026 Source:Scientists Discover Game-Changing New Way To Treat High Cholesterol Reference: A human iPSC-derived hepatocyte screen identifies compounds that inhibit production of Apolipoprotein B